AQS: Aequus Pharmaceuticals Inc. - Summary | Jitta

Aequus Pharmaceuticals Inc.

CAN:AQS

Price
CA$0.04
Loss Chance
57.8%
1.43JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
97 / 110
1,770 / 1,934
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (13)
Recent Business Performance (11)
Financial Strength (34)
Return to Shareholders (13)
Competitive Advantage (29)
Jitta Signs
Revenue and EarningEarning loss detected in 2022
Operating MarginDeclined
Recent Business PerformanceEarning decline 98.84% in the last year
New Share IssuedMore than 50% in 5 years
CapExVery High
Key Stats
Jitta Score
Jitta Line
1.43
100.00%
2.13
70.28%
2.40
107.49%
Pharmaceuticals
4.12
84.24%
4.12
84.24%
3.07
345.14%
COMPANY DESCRIPTION
Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, develops and commercializes drugs in Canada. It focuses on various therapeutic areas, including neurology, ophthalmology, and transplantation. The company markets Vistitan, an ophthalmology product to reduce elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Tacrolimus IR, an immunosuppressant for the treatment and prevention of acute rejection following organ transplantation; Evolve dry eye products for various symptoms involved with dry eye disease and blepharitis, including discomfort, stinging, burning, and dryness; and preservative free ophthalmic product. Its development stage product includes Topiramate XR and Oxcarbazepine XR extended-release oral tablets for the treatment of epilepsy; AQS1303, a transdermal pyridoxine/doxylamine for the treatment of nausea and vomiting of pregnancy; and AQS1304, a cannabinoid based therapeutics for neurological disorders. The company has collaboration agreements with Sandoz Canada, Inc. for the promotion of Vistitan; Supernus Pharmaceuticals, Inc. for marketing of extended-release anti-epileptic drugs; and Medicom Healthcare Ltd. to focus on preservative free therapies in ophthalmology. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.